I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at


Coming soon
08:30 AM
Duration 4mins Virtual
Faricimab▼ Rapidly Improves Fluid Parameters in Patients With nAMD
Gale R, London N, Kotecha A, Willis J, Souverain A, Shildkrot E, Margaron P
Duration 4mins Virtual
Baseline characteristics and 3 month data from patients receiving faricimab▼ for nAMD or DME in the real-world VOYAGER study
Sheth V, Bailey C, Bengus M, Chaikitmongkol V, Chaudhary V, Chi G, Finger R, Gallego R, Gilberg R, Koh A, Ishida S, Lövestam M, Parravano M, Luna Pinto JD, Scheidl S, Schmitz-Valckenberg MS, Souied E, Guymer R
Duration 4mins Virtual
Burden in the Clinical Management of Diabetic Macular Edema: A Multicenter Analysis in the UK
Peto T, Chen X, Talks S, Menon G, Ghanchi F, Shah P, Yang Q, Ferrara D, Adesanya L, Chi G
Duration 4mins Virtual
Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pavilion Trial
Wykoff C, Chang M, Emanuelli A, Holekamp N, Latkany P, Malhotra V, Brittain C, Howard D, Santhanakrishnan A, Wetzel-Smith M, Quezada-Ruiz C, Pieramici D
Duration 4mins Virtual
Refill-Exchange Procedure for the Port Delivery System with Ranibizumab: Optimisation and Enhanced Training
Becker M, Colina J, Graff J, Kitchens J, Thompson J, Malhotra V, Menezes A, Patel S, Singh N, Utley S, Vicente A, Jaycock P
Duration 4mins Virtual
FARWIDE-DME: early treatment patterns of faricimab▼ among DME patients in the UK
Bailey C, Peto T, Downey L, Kiire C, Pearce I, Reynolds R, Sivaprasad S, Chi G, James N, Downey A, Shah P, Dodds M, Dayal P
12:19 PM
09:07 AM
09:16 AM
11:07 AM
Duration 6mins Room E102
Port Delivery System With Ranibizumab in Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pagoda Trial
Graff J, Marcus D, Campochiaro P, Rahman S, Malhotra V, Latkany P, Gune S, DeGraaf S, Bobbala A, Rabena M, Quezada-Ruiz C, Khanani A
11:13 AM
11:19 AM
12:18 PM
01:03 PM
03:46 PM
Duration 6mins Room E102
Faricimab▼ Personalised Treat-and-Extend–Based Dosing Dynamics in Patients With DME
Figueroa M, Pearce I, Lim J, Gibson K, Jain N, Souverain A, Yang M, Willis J, Haskova Z
09:25 AM
Duration 6mins Room E102
Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With Diabetic Macular Edema
Sivaprasad S, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, Wang T, Haskova Z, Amador M, Mar F, Goldberg R
12:19 PM
Duration 6mins Room E102
A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study
Pavesio C, Sharma S, Suhler E, Lin P, Pauly-Evers M, Willen D, Peck R, Storti F, Rauhut S, Gott T, Passemard B, Macgregor L, Haskova Z, Silverman D, Fauser S, Mesquida M
12:36 PM
Duration 5mins Speakers Corner
FARWIDE-nAMD: early treatment patterns of faricimab▼ among neovascular age-related macular degeneration (nAMD) patients in the UK
Talks J, De Salvo G, Patel P, de Silva S, Gale R, Varma D, McKibbin M, James N, Downey A, Shah P, Dodds M, Dayal P, Chi G
03:30 PM
03:43 PM